 In Q2, Corbus Pharmaceuticals NASDAQ: CRBP posted sales of 286.35 thousand. Earnings were up 27.62, but Corbus Pharmaceuticals still reported an overall loss of 38.14 million. Corbus Pharmaceuticals collected 1.76 million in revenue during Q1, but reported earnings showed a 29.89 million loss.What Is ROCE? Changes in earnings and sales indicate shifts in Corbus Pharmaceuticalss Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Corbus Pharmaceuticals posted an ROCE of -0.79.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a companys recent performance, but several factors could affect earnings and sales in the near future.View more earnings on CRBPROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Corbus Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.For Corbus Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q2 Earnings Insight Corbus Pharmaceuticals reported Q2 earnings per share at -0.52share, which did not meet analyst predictions of -0.39share.See more from Benzinga Stocks That Hit 52-Week Highs On WednesdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 